Rogers (ROG) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Needham & Company Raises Price Target on Rogers (ROG) to $75 Following Solid 3Q
November 4, 2016 8:26 AM EDTNeedham & Company reiterated a Buy rating on Rogers Corp (NYSE: ROG), and raised the price target to $75.00 (from $70.00), following the company's 3Q earnings report. ROG reported revenues of $165M and EPS of $0.95, above prior guidance for $150-160M and adjusted EPS of $0.69-0.79. Previous consensus... More
Genentech (RHHBY) Plans Presentation of New Actemra, Rituxan Data at 2016 ACR/ARHP Annual Meeting
November 2, 2016 6:27 AM EDTGenentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 11-16, Washington, D.C. These data add to the significant body of evidence for Actemra and Rituxan in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Advances in our scientific understanding behind immune pathways are guiding the development of potential new treatments for severe... More
Trading Radar for 11/2: Facebook (FB), Qualcomm (QCOM), Alibaba (BABA), Yelp (YELP), Allstate (ALL), Fitbit (FIT) Report
November 1, 2016 2:56 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:15am EDT
Earnings:
1-800-FLOWERS.com (NYSE: FLWS) - consensus loss $0.23
Alibaba (NYSE: BABA) - consensus EPS $0.69
Alkermes plc (Nasdaq: ALKS) - consensus loss $0.06
Allergan (NYSE: AGN) - consensus EPS $3.65
AmerisourceBergen (NYSE: ABC) - consensus EPS... More



